

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: **Buprenorphine Naloxone BNM**
Active Ingredients: Buprenorphine hydrochloride 2.16mg equivalent to buprenorphine 2mg
 Naloxone hydrochloride dihydrate 0.61mg equivalent to naloxone 0.5mg
Dosage Form: Sublingual tablet
New Zealand Sponsor: Boucher & Muir (New Zealand) Limited t/a BNM Group
Manufacturer: G.L. Pharma GmbH, Lannach, Austria

Product: **Buprenorphine Naloxone BNM**
Active Ingredients: Buprenorphine hydrochloride 8.64mg equivalent to buprenorphine 8mg
 Naloxone hydrochloride dihydrate 2.44mg equivalent to naloxone 2mg
Dosage Form: Sublingual tablet
New Zealand Sponsor: Boucher & Muir (New Zealand) Limited t/a BNM Group
Manufacturer: G.L. Pharma GmbH, Lannach, Austria

Product: **Jinarc**
Active Ingredient: Tolvaptan 15mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Otsuka Pharmaceutical Co Limited, Tokushima, Japan

Product: **Jinarc**
Active Ingredient: Tolvaptan 30mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Otsuka Pharmaceutical Co Limited, Tokushima, Japan

Product: **Jinarc (Combination Product)**
Component 1:
Active Ingredient: Tolvaptan 15mg
Dosage Form: Tablet
Component 2:
Active Ingredient: Tolvaptan 45mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Otsuka Pharmaceutical Co Limited, Tokushim, Japan

Product: **Jinarc (Combination Product)**
Component 1:
Active Ingredient: Tolvaptan 30mg
Dosage Form: Tablet
Component 2:
Active Ingredient: Tolvaptan 60mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Otsuka Pharmaceutical Co Limited, Tokushim, Japan

Product: **Jinarc (Combination Product)**
Component 1:
Active Ingredient: Tolvaptan 30mg
Dosage Form: Tablet
Component 2:
Active Ingredient: Tolvaptan 90mg
Dosage Form: Tablet
New Zealand Sponsor: Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics
Manufacturer: Otsuka Pharmaceutical Co Limited, Tokushim, Japan

NEW ZEALAND GAZETTE

<i>Product:</i>	Plenvu
Component 1:	
<i>Active Ingredients:</i>	Macrogol 3350 100g Potassium chloride 1g Sodium chloride 2g Sodium sulfate 9g
<i>Dosage Form:</i>	Powder for oral solution
Component 2:	
<i>Active Ingredients:</i>	Macrogol 3350 40g Potassium chloride 1.2g Sodium chloride 3.2g
<i>Dosage Form:</i>	Powder for oral solution
Component 3:	
<i>Active Ingredients:</i>	Ascorbic acid 7.54g Sodium ascorbate 48.11g
<i>Dosage Form:</i>	Powder for oral solution
<i>New Zealand Sponsor:</i>	CARSL Consulting
<i>Manufacturers:</i>	Norgine (UK) Limited, Hengoed, United Kingdom

Dated this 13th day of May 2019.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

2019-go2231

16-05-2019 09:02
